• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

JCI Insight. The laboratory tests and host immunity of COVID-19 patients with different severity of illness

tetano

Editor, Senior Moderator
JCI Insight. 2020 Apr 23. pii: 137799. doi: 10.1172/jci.insight.137799. [Epub ahead of print]
The laboratory tests and host immunity of COVID-19 patients with different severity of illness.


Wang F[SUP]1[/SUP], Hou H[SUP]1[/SUP], Luo Y[SUP]1[/SUP], Tang G[SUP]1[/SUP], Wu S[SUP]1[/SUP], Huang M[SUP]1[/SUP], Liu W[SUP]1[/SUP], Zhu Y[SUP]1[/SUP], Lin Q[SUP]1[/SUP], Mao L[SUP]1[/SUP], Fang M[SUP]2[/SUP], Zhang H[SUP]3[/SUP], Sun Z[SUP]1[/SUP].

Author information




Abstract

BACKGROUND:

The Coronavirus Disease-2019 (COVID-19), infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused a severe outbreak in China. The host immunity of COVID-19 patients is unknown.
METHODS:

The routine laboratory tests and host immunity in COVID-19 patients with different severity of illness were compared after patient admission.
RESULTS:

A total of 65 SARS-CoV-2-positive patients were classified as mild (n=30), severe (n=20), and extremely severe (n=15) illness. Many routine laboratory tests such as ferritin, lactate dehydrogenase and D-dimer were increased in severe and extremely severe patients. The absolute numbers of CD4+ T cells, CD8+ T cells and B cells were all gradually decreased with increased severity of illness. The activation markers such as HLA-DR and CD45RO expressed on CD4+ and CD8+ T cells were increased in severe and extremely severe patients compared with mild patients. The co-stimulatory molecule CD28 had opposite results. The percentage of natural regulatory T cells was decreased in extremely severe patients. The percentage of IFN-γ producing CD8+ T cells was increased in both severe and extremely severe patients compared with mild patients. The percentage of IFN-γ producing CD4+ T cells was increased in extremely severe patients. The IL-2R, IL-6, and IL-10 were all increased in extremely severe patients. The activation of DC and B cells was decreased in extremely severe patients.
CONCLUSIONS:

The number and function of T cells are inconsistent in COVID-19 patients. The hyperfunction of CD4+ and CD8+ T cells is associated with the pathogenesis of extremely severe SARS-CoV-2 infection.



KEYWORDS:

Adaptive immunity; Cellular immune response; Immunology; Infectious disease; Innate immunity


PMID:32324595DOI:10.1172/jci.insight.137799
 
Back
Top Bottom